← All candidates
49 insider filings on record.
49 filings on record.
NVCRNovoCure Ltd
—
$17.88
+2.94% · Jul 9
49 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 4 buys● 8 sells◆ 7 8-K
▸ hover a marker for the filing · drag to zoom · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Chief Executive Officer
Cordova Ashley
Bought $996.9K on Sep 5 — 81,550 sh @ $12.22, held direct, 19% of their stake.
1 of 1 position beat the S&P
Chief Financial Officer
Brackmann Christoph
Bought $116.3K on Jul 29 — 10,000 sh @ $11.63, held direct, 7.6% of their stake.
1 of 1 position beat the S&P
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
44 more transactions on Pro →Context
Wall St
$26.00 avg target
+45.4% vs today · 7 analysts · consensus Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26−$0.62 act−$0.11
Q4 '25−$0.22 act+$0.19
Q3 '25−$0.33 act+$0.09
Q2 '25−$0.36 act+$0.03
Coverage
NovoCure's Cancer Treatment Device Option Pax Gets European ApprovalZacks · 07-01HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?Motley Fool · 06-24NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?Motley Fool · 06-22NovoCure (NVCR) Stock Could Be 45.2% Below Fair Value After TRIDENT Trial MissSimply Wall St. · 06-20
The file stays open
49 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice